Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors J. Kay Noel, Kazunori Iwata, Shinsuke Ooike, Kunio Sugahara, Hideo Nakamura, Masanori Daibata
Title Abstract C244: Development of the BET bromodomain inhibitor OTX015.
Abstract Text Mol Cancer Ther November 2013 12:C244; doi:10.1158/1535-7163.TARG-13-C244


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Birabresib Birabresib 12 3
Drug Name Trade Name Synonyms Drug Classes Drug Description
Birabresib Y-803|MK-8628|OTX015|OTX-015 BET Inhibitor (Pan) 30 Birabresib (OTX015) is an inhibitor of the BET bromodomain proteins BRD3, BRD4, and BRD5, which inhibits interaction with acetylated histone H4, potentially resulting in decreased tumor cell proliferation (Mol Cancer Ther Nov 2013 12:C244, PMID: 29733771, PMID: 31204545).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown NUT midline carcinoma not applicable Birabresib Preclinical - Cell line xenograft Actionable In a preclinical study, Birabresib (OTX015) inhibited tumor growth in cell line xenograft models of NUT midline carcinoma (Mol Cancer Ther November 2013 12; C244). detail...
Unknown unknown Advanced Solid Tumor not applicable Birabresib Preclinical - Cell culture Actionable In a preclinical study, Birabresib (OTX015) inhibited growth of a variety of tumor cell lines in cell culture (Mol Cancer Ther November 2013 12; C244). detail...